Tuesday, January 27, 2015 9:13:05 PM
The pros for Vaccination-
1. It's a word well understood in the West- and in civilized society around the world- so there is a willingness to fund it.
2. It works well in some cases- particularly when it is used against a relatively stable virus.
3. Vaccination changed the course of treatment and saved many lives when it was first introduced.
4. It is good for at least a season or more in most cases.
The Cons for vaccination (Ebola in particular)
1. Very expensive and very manpower draining to vaccinate a whole region
2. Africans are skeptical about getting needles from 'The West' as they have seen too many of their people carted off to hospitals never to return.
3. EBOLA is a moving target and a mutation prone virus. Vaccination is restricted to one strain at a time.
4. The next EBOLA outbreak could be in a different place and involve a different strain- necessitating a mass effort, and demanding money and resources
5. A huge number of doses has to be prepared- in a hurry- requiring a facility and available staff- even tho perhaps less than 1% of the population being inoculated would be likely to contract the disease.
6. Vaccinations require teams of people- setting up temporary clinics or travelling the countryside.
Pros for NNVC:
1. Only those diagnosed need to be treated, and that can happen at established clinics or hospitals/ or in traveling dispensaries.
2. Mutation resistant- all strains are likely to be treatable with one medication
3. Hundred-fold to thousand-fold reduction on demand for personnel and resources
4. Since patients are the only ones treated, number of doses needed is more manageable to produce. (NNVC can supply all needs worldwide)
5. Ebolacide is likely to have enough prophylactic effect to protect medical personnel.
Cons for NNVC
1. New paradigm (like vaccination before it became a standard)- thus lots of skeptics
2. Has yet to be proven and understood (tick ...tick...tick)
3. Hmmm running out of ideas... help?
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM